MOTS-c
MOTS-c is a mitochondrial-derived peptide under FDA review.
- Routesubcutaneous injection
- Baseline labsNot typically required
- EvidenceLimited human data
- AvailabilityEducation only
How it works
MOTS-c is a mitochondrial-derived peptide under FDA review.
What it's been studied for
- Structure/function pathways relevant to its category
- Research contexts that vary in quality and quantity
“Studied for” describes what research has examined — not a promise of any outcome for you.
What the evidence says
Human data for this peptide is limited. A licensed provider can discuss what the current evidence does and does not support for you.
What to expect at Clyne
Prescription-only and physician-reviewed. A licensed provider decides whether it's appropriate for you; where it isn't available to prescribe, you can join a waitlist instead.
Safety & considerations
Human data for this peptide is limited. A licensed provider can discuss what the current evidence does and does not support for you. Your provider screens your history and medications and can decline if it isn't right for you.
Regulatory status
This peptide is currently under FDA review for compounding and is not available to prescribe. It is on the FDA's PCAC agenda (docket FDA-2025-N-6895). A regulatory category that permits compounding is not the same as FDA approval.
Common questions
How strong is the evidence?
Human data for this peptide is limited. A licensed provider can discuss what the current evidence does and does not support for you.
Join the waitlist
MOTS-c isn't currently available. Add your email and we'll notify you if its status changes — no charge, no commitment.
